From: Prognostic value of S100A4 and Glypican-3 in hepatocellular carcinoma in cirrhotic HCV patients
 | Median overall survival (95% CI) | Log rank (Mantel-Cox) | p-value |
---|---|---|---|
Sex | |||
 Male | 6 (2–9.9) | 0.276 | 0.600 |
 Female | 3 (0–21) | ||
S100 | |||
 Positive | 9 (1.7–16.2) | 0.585 | 0.444 |
 Negative | 6 (1.9–10.05) | ||
Glypican | |||
 Positive | 5 (0–10.6) | 1.327 | 0.249 |
 Negative | 8 (3.3–12.6) | ||
Decompensation | |||
 Yes | 2 (0.2–3.7) | 3.79 | 0.012* |
 No | 9 (7.5–10.5) | ||
Recurrence | |||
 Yes | 6 (0–15.4) | 0.381 | 0.537 |
 No | 8 (3.8–12.15) | ||
Metastasis | |||
 Yes | 3 (0–6.6) | 0.165 | 0.684 |
 No | 8 (4.4–11.5) | ||
Necrosis | |||
 Yes | 4 (1.5–6.4) | 1.835 | 0.176 |
 No | 9 (5.3–12.7) | ||
Microscopic vascular emboli | |||
 Yes | 9 (1.6–16.4) | 0.037 | 0.848 |
 No | 6 (2.02–9.9) | ||
Grading | |||
 1 | 10 (2.7–17.3) | 6.164 | 0.046* |
 2 | 3 (0.6–5.35) | ||
 3 | 5 (0–12.5) |